These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
313 related articles for article (PubMed ID: 14998494)
1. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Hurt EM; Wiestner A; Rosenwald A; Shaffer AL; Campo E; Grogan T; Bergsagel PL; Kuehl WM; Staudt LM Cancer Cell; 2004 Feb; 5(2):191-9. PubMed ID: 14998494 [TBL] [Abstract][Full Text] [Related]
2. c-maf in multiple myeloma: an oncogene enhancing tumor-stroma interactions. Kienast J; Berdel WE Cancer Cell; 2004 Feb; 5(2):109-10. PubMed ID: 14998484 [TBL] [Abstract][Full Text] [Related]
3. TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines. Moreaux J; Hose D; Jourdan M; Reme T; Hundemer M; Moos M; Robert N; Moine P; De Vos J; Goldschmidt H; Klein B Haematologica; 2007 Jun; 92(6):803-11. PubMed ID: 17550853 [TBL] [Abstract][Full Text] [Related]
4. CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells. Tai YT; Soydan E; Song W; Fulciniti M; Kim K; Hong F; Li XF; Burger P; Rumizen MJ; Nahar S; Podar K; Hideshima T; Munshi NC; Tonon G; Carrasco RD; Afar DE; Anderson KC Blood; 2009 Apr; 113(18):4309-18. PubMed ID: 19196658 [TBL] [Abstract][Full Text] [Related]
5. C-MAF oncogene dysregulation in multiple myeloma: frequency and biological relevance. Rasmussen T; Knudsen LM; Dahl IM; Johnsen HE Leuk Lymphoma; 2003 Oct; 44(10):1761-6. PubMed ID: 14692531 [TBL] [Abstract][Full Text] [Related]
6. Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. Neri P; Ren L; Azab AK; Brentnall M; Gratton K; Klimowicz AC; Lin C; Duggan P; Tassone P; Mansoor A; Stewart DA; Boise LH; Ghobrial IM; Bahlis NJ Blood; 2011 Jun; 117(23):6202-13. PubMed ID: 21474670 [TBL] [Abstract][Full Text] [Related]
7. Overexpression of c-Maf contributes to T-cell lymphoma in both mice and human. Morito N; Yoh K; Fujioka Y; Nakano T; Shimohata H; Hashimoto Y; Yamada A; Maeda A; Matsuno F; Hata H; Suzuki A; Imagawa S; Mitsuya H; Esumi H; Koyama A; Yamamoto M; Mori N; Takahashi S Cancer Res; 2006 Jan; 66(2):812-9. PubMed ID: 16424013 [TBL] [Abstract][Full Text] [Related]
9. The ubiquitin-conjugating enzyme UBE2O modulates c-Maf stability and induces myeloma cell apoptosis. Xu Y; Zhang Z; Li J; Tong J; Cao B; Taylor P; Tang X; Wu D; Moran MF; Zeng Y; Mao X J Hematol Oncol; 2017 Jul; 10(1):132. PubMed ID: 28673317 [TBL] [Abstract][Full Text] [Related]
10. Chromatin-based, in cis and in trans regulatory rewiring underpins distinct oncogenic transcriptomes in multiple myeloma. Alvarez-Benayas J; Trasanidis N; Katsarou A; Ponnusamy K; Chaidos A; May PC; Xiao X; Bua M; Atta M; Roberts IAG; Auner HW; Hatjiharissi E; Papaioannou M; Caputo VS; Sudbery IM; Karadimitris A Nat Commun; 2021 Sep; 12(1):5450. PubMed ID: 34521827 [TBL] [Abstract][Full Text] [Related]
11. Identification of small compounds that inhibit multiple myeloma proliferation by targeting c-Maf transcriptional activity. Asano K; Kikuchi K; Takehara M; Ogasawara M; Yoshioka Y; Ohnishi K; Iwata A; Shimizu S; Tanaka M Biochem Biophys Res Commun; 2023 Dec; 684():149135. PubMed ID: 37879249 [TBL] [Abstract][Full Text] [Related]
12. A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin. Mao X; Stewart AK; Hurren R; Datti A; Zhu X; Zhu Y; Shi C; Lee K; Tiedemann R; Eberhard Y; Trudel S; Liang S; Corey SJ; Gillis LC; Barber DL; Wrana JL; Ezzat S; Schimmer AD Blood; 2007 Dec; 110(12):4047-54. PubMed ID: 17875808 [TBL] [Abstract][Full Text] [Related]
13. Targeting the oncogenic transcription factor c-Maf for the treatment of multiple myeloma. Jiang Q; Mao H; He G; Mao X Cancer Lett; 2022 Sep; 543():215791. PubMed ID: 35700821 [TBL] [Abstract][Full Text] [Related]
14. Adhesive interactions between tumour cells and bone marrow stromal elements in human multiple myeloma. Faid L; Van Riet I; De Waele M; Facon T; Schots R; Lacor P; Van Camp B Eur J Haematol; 1996 Nov; 57(5):349-58. PubMed ID: 9003475 [TBL] [Abstract][Full Text] [Related]
15. Long non-coding RNA ANGPTL1-3 promotes multiple myeloma bortezomib resistance by sponging miR-30a-3p to activate c-Maf expression. Nian F; Zhu J; Chang H Biochem Biophys Res Commun; 2019 Jul; 514(4):1140-1146. PubMed ID: 31103265 [TBL] [Abstract][Full Text] [Related]
16. Expression of adhesion molecules in malignant plasma cells in multiple myeloma: comparison with normal plasma cells and functional significance. Helfrich MH; Livingston E; Franklin IM; Soutar RL Blood Rev; 1997 Mar; 11(1):28-38. PubMed ID: 9218104 [TBL] [Abstract][Full Text] [Related]
17. Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment. Corso A; Ferretti E; Lazzarino M Hematology; 2005 Jun; 10(3):215-24. PubMed ID: 16019470 [TBL] [Abstract][Full Text] [Related]
18. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation. Nguyen AN; Stebbins EG; Henson M; O'Young G; Choi SJ; Quon D; Damm D; Reddy M; Ma JY; Haghnazari E; Kapoun AM; Medicherla S; Protter A; Schreiner GF; Kurihara N; Anderson J; Roodman GD; Navas TA; Higgins LS Exp Cell Res; 2006 Jun; 312(10):1909-23. PubMed ID: 16600214 [TBL] [Abstract][Full Text] [Related]